Publications by authors named "Timothy A Donnison"
Chronic hepatitis B virus (HBV) infection affects 257 million people globally. Current therapies suppress HBV but viral rebound occurs on cessation of therapy; novel therapeutic strategies are urgently required. To develop a therapeutic HBV vaccine that can induce high magnitude T cells to all major HBV antigens, we have developed a novel HBV vaccine using chimpanzee adenovirus (ChAd) and modified vaccinia Ankara (MVA) viral vectors encoding multiple HBV antigens.
View Article and Find Full Text PDFArticle Synopsis
- Hepatitis C poses a challenge for vaccine development due to its genomic variability, which affects T-cell responses to the virus; previous research showed T-cell responses from a first-generation vaccine targeting a specific HCV subtype are limited by this variability.
- The researchers created a second-generation vaccine using a computer algorithm to identify conserved genomic segments across various HCV genotypes, constructing simian adenoviral vectors that incorporate these segments.
- Testing in mice showed that the new vaccine (ChAdOx1) produced strong and diverse T-cell responses against multiple HCV subtypes, indicating potential effectiveness in humans based on the conserved nature of the immunogens used.